Compare HNNA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | VNRX |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | HNNA | VNRX |
|---|---|---|
| Price | $10.32 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.17 |
| AVG Volume (30 Days) | 8.9K | ★ 2.6M |
| Earning Date | 12-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 38.04 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $35,538,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.33 |
| Revenue Next Year | N/A | $493.79 |
| P/E Ratio | $7.87 | ★ N/A |
| Revenue Growth | ★ 19.88 | 14.48 |
| 52 Week Low | $8.43 | $0.27 |
| 52 Week High | $13.88 | $0.94 |
| Indicator | HNNA | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 35.58 |
| Support Level | $9.33 | $0.27 |
| Resistance Level | $10.39 | $0.33 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 61.47 | 31.95 |
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.